Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes drugs may reverse fatty liver damage in new trial

NCT ID NCT04639414

Completed Disease control Sponsor: German Diabetes Center Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study tests whether combining two diabetes drugs—semaglutide and empagliflozin—can reverse liver damage from NASH (a severe form of fatty liver disease) in people with type 2 diabetes. Participants will receive either the combo, empagliflozin alone, or a placebo for 48 weeks. The main goal is to see if the treatment clears NASH without worsening liver scarring.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Semaglutide and empagliflozin
What this could lead to
If successful, this combination could offer a new way to treat NASH in people with type 2 diabetes, potentially reversing liver damage and reducing the need for separate medications.
What could go wrong
This is a Phase 4 trial, but NASH is a complex disease and previous treatments have failed. The drugs may not improve liver health, and side effects like gastrointestinal issues or hypoglycemia are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus fatty liver disease metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) TYPE 2 DIABETES

Contacts and locations

Locations

  • Eugastro GmbH

    Leipzig, 04103, Germany

  • Franziskus-Krankenhaus Berlin

    Berlin, 10787, Germany

  • German Diabetes Center

    Düsseldorf, North Rhine-Westphalia, 40225, Germany

  • Herz- und Diabeteszentrum NRW

    Bad Oeynhausen, 32545, Germany

  • Leber- und Studienzentrum Checkpoint

    Berlin, 10961, Germany

  • Medizinische Universität Graz

    Graz, 8010, Austria

  • Medizinische Universität Innsbruck

    Innsbruck, Austria

  • Medizinische Universität Wien

    Vienna, Austria

  • Städtisches Klinikum Brandenburg GmbH

    Brandenburg, 14770, Germany

  • Städtisches Klinikum Braunschweig gGmbH

    Braunschweig, 38126, Germany

  • TUM

    München, 81675, Germany

  • University Clinics Berlin Charité

    Berlin, 12200, Germany

  • University Clinics Berlin Charité

    Berlin, 13353, Germany

  • University Clinics Bochum

    Bochum, 44892, Germany

  • University Clinics Carl Gustav Carus Dresden

    Dresden, 01307, Germany

  • University Clinics Essen

    Essen, 45147, Germany

  • University Clinics Frankfurt

    Frankfurt, 60590, Germany

  • University Clinics Freiburg

    Freiburg im Breisgau, 79106, Germany

  • University Clinics Heidelberg

    Heidelberg, 69120, Germany

  • University Clinics Johannes-Gutenberg Mainz

    Mainz, 55131, Germany

  • University Clinics Tübingen

    Tübingen, 72076, Germany

  • University Clinics Würzburg

    Würzburg, 97080, Germany

  • Universitätsklinikum Düsseldorf

    Düsseldorf, 40225, Germany

  • Universitätsklinikum Ulm

    Ulm, 89081, Germany

  • Wiener Gesundheitsverbund, Klinik Hietzing

    Vienna, Austria

  • Wiener Gesundheitsverbund, Klinik Landstraße

    Vienna, 1030, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.